HENDERSON, Nev., Oct. 18, 2023 - VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, welcomed Ambassador Michael M. Adler, U.S. Ambassador to the Kingdom of Belgium for a tour of its purpose-built research, development and manufacturing facilities situated in Isnes, Belgium.
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis.
Gaetan Michel, Chief Operating Officer at Volition, said: "We were delighted to welcome Ambassador Adler to Volition today, to introduce our expert team, showcase our transformative epigenetic technology, and highlight its potential to improve patient outcomes worldwide.
"With purpose-built R&D and manufacturing facilities in Belgium and a state-of-the-art innovation lab in California, Volition has operations on both sides of the Atlantic. As a company, we benefit enormously from this talent pool, joint working, and shared experience and it has undoubtedly accelerated our growth.
"Ambassador Adler's visit today was an ideal opportunity for us to celebrate this collaborative work and highlight the close ties we have fostered between U.S. and Belgian stakeholders over the last 13 years. Our subsidiary, Volition Veterinary Diagnostics Development LLC was borne out of a collaboration with Texas A&M University and enabled us to launch the Nu.Q® Vet Cancer Test commercially within the United States. Cultivating successful, ongoing relationships with stakeholders worldwide has been fundamental to Volition's development."
Volition's existing product portfolio comprises Nu.Q® Cancer Vet Test, a diagnostic aid for the early detection and monitoring of cancer in dogs, and Nu.Q® NETs, a CE Marked test to detect diseases associated with NETosis. For more information go to: www.volition.com
About Volition
Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost- effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
The contents found at the Volition website address are not incorporated by reference into this document and should not be considered part of this document. The website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to the timing and launch of product sales, and the potential uses, benefits and effectiveness of its Nu.Q® products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests, a failure by the marketplace to accept Volition's Nu.Q® tests; Volition's failure to secure adequate intellectual property protection; Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition will face fierce competition and its intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Forward-looking statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
